ArticleFrontiers in oncology2026

Correction: Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib.

Furong Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.